Selected Publications

1. Ackermann, U., et al. (2023). “18F-labeling and initial in vivo evaluation of a Hitomi peptide for imaging tissue transglutaminase 2.” Nuclear Medicine and Biology 116: 108308.

2. Aguado, L., et al. (2023). “Therapeutic effect of α 7 nicotinic receptor activation after ischemic stroke in rats.” Journal of Cerebral Blood Flow & Metabolism: 0271678X231161207.

3. Ahenkorah, S., et al. (2023). “Direct comparison of [18F] AlF-NOTA-JR11 and [18F] AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist.” Nuclear Medicine and Biology 118: 108338.

4. Altomonte, S., et al. (2023). “Discovery of a High-Affinity Fluoromethyl Analog of [11C] 5-Cyano-N-(4-(4-methylpiperazin-1-yl)-2-(piperidin-1-yl) phenyl) furan-2-carboxamide ([11C] CPPC) and Their Comparison in Mouse and Monkey as Colony-Stimulating Factor 1 Receptor Positron Emission Tomography Radioligands.” ACS Pharmacology & Translational Science 6(4): 614-632.

5. Alves, R. C., et al. (2023). “Folic acid-conjugated curcumin-loaded bioMOF-101 for breast cancer therapy.” Journal of Drug Delivery Science and Technology: 104702.

6. Andersen, K. B., et al. (2023). “Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [11C] UCB‐J and [18F] FDG PET Study.” Movement Disorders.

7. Arteaga, A., et al. (2023). “A Model Study to Evaluate Osseointegration and Fracture Healing Following Open Reduction and Internal Fixation (ORIF) in Diabetic Lewis Rats.” The Journal of Foot and Ankle Surgery.

8. Ballweg, A., et al. (2023). “[18F] F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data.” Journal of Neuroinflammation 20(1): 68.

9. Bartos, L. M., et al. (2023). “Deciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution.” bioRxiv: 2023.2001. 2026.522174.

10. Beall, M., et al. (2023). “Prognostic Value of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Predicting Venous Thromboembolism in Children With Lymphoma.” Circulation: Cardiovascular Imaging 16(4): e014992.

11. Bhaidana, H. and D. Paikaray (2023). PET Imaging for Alzheimer’s Neuroanatomical Disease Diagnosis. 2023 International Conference on Artificial Intelligence and Smart Communication (AISC), IEEE.

12. Bilbao‐Asensio, M., et al. (2023). “Redox‐Triggered Nanomedicine via Lymphatic Delivery: Inhibition of Melanoma Growth by Ferroptosis Enhancement and a Pt (IV)‐Prodrug Chemoimmunotherapy Approach.” Advanced Therapeutics 6(2): 2200179.

13. Bonaventura, J., et al. (2023). “Expression of the excitatory opsin ChRERα can be traced longitudinally in rat and nonhuman primate brains with PET imaging.” Science Translational Medicine 15(706): eadd1014.

14. Bouter, C., et al. (2023). “Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice.” Journal of Neural Transmission: 1-15.

15. Brosch-Lenz, J., et al. (2023). “Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy.” Journal of Nuclear Medicine 64(5): 767-774.

16. Brown, K. G., et al. (2023). “Assessment of Transarterial Chemoembolization Using Super-resolution Ultrasound Imaging and a Rat Model of Hepatocellular Carcinoma.” Ultrasound in medicine & biology 49(5): 1318-1326.

17. Brumberg, J., et al. (2023). “Quantification of the purinergic P2X7 receptor with [11C] SMW139 improves through correction for brain-penetrating radiometabolites.” Journal of Cerebral Blood Flow & Metabolism 43(2): 258-268.

18. Buechel, R. R., et al. (2023). “Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study.” European Journal of Nuclear Medicine and Molecular Imaging: 1-10.

19. Cai, L., et al. (2023). “Candidate 3-benzazepine-1-ol type GluN2B receptor radioligands (11C-NR2B-Me enantiomers) have high binding in cerebellum but not to σ1 receptors.” EJNMMI research 13(1): 1-11.

20. Campión, R., et al. (2023). “Zein-based nanospheres and nanocapsules for the encapsulation and oral delivery of quercetin.” International Journal of Pharmaceutics: 123216.

21. Ceyzériat, K., et al. (2023). “Reactive astrocytes mediate TSPO overexpression in response to sustained CNTF exposure in the rat striatum.” Molecular Brain 16(1): 1-11.

22. Chang, K.-W., et al. (2023). “The Titrated Mannitol Improved Central [99mTc] Tc TRODAT-1 Uptake in an Animal Model—A Clinically Feasible Application.” International Journal of Molecular Sciences 24(4): 3773.

23. Chapeau, D., et al. (2023). “[212Pb] Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors.” Pharmaceuticals 16(7): 985.

24. Chen, C.-W., et al. (2023). “Amygdala substructure volumes and serotonin transporter in first-episode, drug-naïve major depressive disorder: A pilot study.” Journal of Psychiatric Research 160: 210-216.

25. Chen, R., et al. (2023). “First total-body kinetic modeling and parametric imaging of dynamic 68Ga-FAPI-04 PET in pancreatic and gastric cancer.” Journal of Nuclear Medicine 64(6): 960-967.

26. Chen, Y., et al. (2023). “18F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging.” Frontiers in Oncology 13: 1047080.

27. Chen, Y.-H., et al. (2023). “Glucose metabolic heterogeneity correlates with pathological features and improves survival stratification of resectable lung adenocarcinoma.” Annals of Nuclear Medicine 37(2): 139-150.

28. Chen, Y.-H., et al. (2023). “The combined tumor-nodal glycolytic entropy improves survival stratification in nonsmall cell lung cancer with locoregional disease.” Nuclear Medicine Communications 44(1): 100-107.

29. Chen, Y.-H., et al. (2023). “Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer.” International Journal of Molecular Sciences 24(4): 3988.

30. Chen, Y.-J., et al. (2023). Assessment of Brown and Beige Adipose Tissue Activation in Mice Using PET/CT Imaging. Thermogenic Fat: Methods and Protocols, Springer: 135-145.

31. Chen, Z., et al. (2023). “Synaptic Loss in Spinocerebellar Ataxia Type 3 Revealed by SV2A Positron Emission Tomography.” Movement Disorders.

32. Cheung, P., et al. (2023). “[18F] MK-7246 for Positron Emission Tomography Imaging of the Beta-Cell Surface Marker GPR44.” Pharmaceutics 15(2): 499.

33. Choen, S., et al. (2023). “Kinetic Evaluation of the Hypoxia Radiotracers [18F] FMISO and [18F] FAZA in Dogs with Spontaneous Tumors Using Dynamic PET/CT Imaging.” Nuclear Medicine and Molecular Imaging 57(1): 16-25.

34. Choi, K.-M., et al. (2023). “Regulation of beige adipocyte thermogenesis by the cold-repressed ER protein NNAT.” Molecular Metabolism 69: 101679.

35. Chotiwan, N., et al. (2023). “Type I interferon shapes brain distribution and tropism of tick-borne flavivirus.” Nature Communications 14(1): 2007.

36. Chou, T.-H., et al. (2023). “Vessel-by-vessel analysis of lower extremity 18F-NaF PET/CT imaging quantifies diabetes-and chronic kidney disease-induced active microcalcification in patients with peripheral arterial disease.” EJNMMI research 13(1): 1-10.

37. Coelho, M., et al. (2023). “Adjustierung der Rechts-Links-Shunt Normwerte für die Lungenperfusionsszintigraphie unter Berücksichtigung von nicht-gebundenem 99mTc.” Nuklearmedizin-NuclearMedicine 62(02): 167-168.

38. Colon-Mesa, I., et al. (2023). “p27 Kip1 Deficiency Impairs Brown Adipose Tissue Function Favouring Fat Accumulation in Mice.” International Journal of Molecular Sciences 24(3): 2664.

39. Cools, R., et al. (2023). “Radiosynthesis and preclinical evaluation of [11C] SNX-ab as an Hsp90α, β isoform-selective PET probe for in vivo brain and tumour imaging.” EJNMMI Radiopharmacy and Chemistry 8(1): 2.

40. Cosialls, R., et al. (2023). “Ammonium trifluoroborate-modified poly (β-aminoesters): A case study for PET-guided in vivo pharmacokinetic studies of a non-viral gene delivery system.” Journal of Controlled Release 358: 739-751.

41. Costa, P. F., et al. (2023). “18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in Men.” Journal of Nuclear Medicine 64(4): 598-604.

42. Cui, Y., et al. (2022). “FDG PET Imaging of the Pain Matrix in Neuropathic Pain Model Rats.” Biomedicines 11(1): 63.

43. Czoty, P. W., et al. (2023). “Association of dopamine D2-like and D3 receptor function with initial sensitivity to cocaine reinforcement in male rhesus monkeys.” Brain Research 1807: 148323.

44. da Cunha-Bang, S., et al. (2023). “The association between brain serotonin transporter binding and impulsivity and aggression in healthy individuals.” Journal of Psychiatric Research 165: 1-6.

45. Dehghankelishadi, P., et al. (2023). “Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.” Journal of Nanobiotechnology 21(1): 102.

46. Destro, G., et al. (2023). “A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.” Nuclear Medicine and Biology 116: 108312.

47. Dias, A. H., et al. (2023). “Multiparametric dynamic whole-body PSMA PET/CT using [68Ga] Ga-PSMA-11 and [18F] PSMA-1007.” EJNMMI research 13(1): 1-13.

48. Diep, Y. N., et al. (2023). “Astrocytic scar restricting glioblastoma via glutamate–MAO-B activity in glioblastoma-microglia assembloid.” Biomaterials Research 27(1): 71.

49. Díez-Villares, S., et al. (2023). “Quantitative PET tracking of intra-articularly administered 89Zr-peptide-decorated nanoemulsions.” Journal of Controlled Release 356: 702-713.

50. Ding, W., et al. (2023). “A Shortened Model for Logan Reference Plot Implemented via the Self-Supervised Neural Network for Parametric PET Imaging.” IEEE Transactions on Medical Imaging.

51. Ding, W., et al. (2023). “Foramen lacerum impingement of trigeminal nerve root as a rodent model for trigeminal neuralgia.” JCI insight 8(11).

52. Dongxiang, W., et al. (2023). “Prediction of outcomes in patients with local recurrent nasopharyngeal carcinoma: development and validation of a four-factor prognostic model integrating baseline characteristics and [18F] FDG PET/CT parameters.” European Radiology 33(4): 2840-2849.

53. Doppler, M., et al. (2023). “Predictive Value of [99mTc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [90Y]-TARE: A Single-Center Experience.” Diagnostics 13(14): 2432.

54. dos Santos, S. N., et al. (2023). “Development of glycan-targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment.” Cancer Nanotechnology 14(1): 1-21.

55. Drescher, R., et al. (2023). “PET/CT of the Spleen with Gallium-Oxine-Labeled, Heat-Damaged Red Blood Cells: Clinical Experience and Technical Aspects.” Diagnostics 13(3): 566.

56. Du, Y., et al. (2023). “[18F] FNDP PET neuroimaging test–retest repeatability and whole-body dosimetry in humans.” European Journal of Nuclear Medicine and Molecular Imaging: 1-7.

57. Du, Y., et al. (2023). “First-in-human imaging using [11C] MDTC: a radiotracer targeting the cannabinoid receptor type 2.” European Journal of Nuclear Medicine and Molecular Imaging: 1-8.

58. Dumont, L., et al. (2023). “Inhibition of the beta-1 adrenergic receptor does not potentiate mirabegron-stimulated human brown adipose tissue thermogenesis.” medRxiv: 2023.2003. 2022.23287600.

59. Eiro, T., et al. (2023). “Dynamics of AMPA receptors regulate epileptogenesis in patients with epilepsy.” Cell Reports Medicine 4(5).

60. Engel, B. J., et al. (2023). “Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging.” Cancers 15(15): 3787.

61. Etter, D., et al. (2023). “Towards universal comparability of pericoronary adipose tissue attenuation: a coronary computed tomography angiography phantom study.” European Radiology 33(4): 2324-2330.

62. Facchin, C., et al. (2023). “Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino-and 6, 6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model.” Cells 12(6): 914.

63. Farn, S.-S., et al. (2023). “Automated Synthesis of [18F] Flumazenil Application in GABAA Receptor Neuroimaging Availability for Rat Model of Anxiety.” Pharmaceuticals 16(3): 417.

64. Fayard, A., et al. (2023). “Functional and neuropathological changes induced by injection of distinct alpha-synuclein strains: A pilot study in non-human primates.” Neurobiology of Disease 180: 106086.

65. Finze, A., et al. (2023). “Individual regional associations between Aβ-, tau-and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies.” Molecular Psychiatry: 1-13.

66. Fozzato, A., et al. (2023). “Manipulating mitochondrial dynamics in the NTS prevents diet-induced deficits in brown fat morphology and glucose uptake.” Life Sciences: 121922.

67. Fozzato, A., et al. (2023). “Manipulating mitochondrial dynamics in the NTS prevents diet-induced deficits in brown fat morphology and glucose uptake.” bioRxiv: 2023.2001. 2004.522581.

68. Fuglø, D., et al. (2023). “Bone Turnover in Patients with Chronic Kidney Disease Stage 5D and Healthy Controls—a Quantitative [18F] Fluoride PET Study.” Molecular Imaging and Biology: 1-9.

69. Galineau, L., et al. (2023). “Glutamatergic synapse in autism: a complex story for a complex disorder.” Molecular Psychiatry 28(2): 801-809.

70. García-García, L., et al. (2023). “The vasodilator naftidrofuryl attenuates short-term brain glucose hypometabolism in the lithium-pilocarpine rat model of status epilepticus without providing neuroprotection.” European Journal of Pharmacology 939: 175453.

71. Gnörich, J., et al. (2023). “Depletion and activation of microglia impact metabolic connectivity of the mouse brain.” Journal of Neuroinflammation 20(1): 47.

72. Guttman, Z., et al. (2023). “Decomposing risky decision-making in methamphetamine use disorder: Behavioral updating and D2 dopamine receptors.” Drug and alcohol dependence 246: 109860.

73. Ha, L. J., et al. (2023). “Hypothalamic neuronal activation in primates drives naturalistic goal-directed eating behavior.” bioRxiv: 2023.2006. 2011.544288.

74. Hata, S., et al. (2023). “Brain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer’s amyloid β‐peptide.” EMBO Molecular Medicine: e17052.

75. Haustein, R., et al. (2023). “C1q and Tumor Necrosis Factor Related Protein 9 Protects from Diabetic Cardiomyopathy by Alleviating Cardiac Insulin Resistance and Inflammation.” Cells 12(3): 443.

76. Hilbrig, C., et al. (2023). “Evaluation of the EPR Effect in the CAM-Model by Molecular Imaging with MRI and PET Using 89Zr-Labeled HSA.” Cancers 15(4): 1126.

77. Hirata, K., et al. (2023). “Altered brain energy metabolism related to astrocytes in Alzheimer′ s disease.” medRxiv: 2023.2003. 2009.23286881.

78. Hiroyama, S., et al. (2023). “Evaluation of an Integrin αvβ3 Radiotracer,[18F] F-FPP-RGD2, for Monitoring Pharmacological Effects of Integrin αv siRNA in the NASH Liver.” Nuclear Medicine and Molecular Imaging: 1-8.

79. Hori, Y., et al. (2023). “Reduced serotonergic transmission alters sensitivity to cost and reward via 5-HT1A and 5-HT1B receptors in monkeys.” bioRxiv: 2023.2002. 2023.529630.

80. Hori, Y., et al. (2023). “Multimodal imaging for validation and optimization of ion channel-based chemogenetics in nonhuman primates.” bioRxiv: 2023.2007. 2006.547946.

81. Horie, S., et al. (2023). “Novel strategy of liver cancer treatment with modified antisense oligonucleotides targeting human vasohibin‐2.” Cancer Science.

82. Iker Etchegaray, J., et al. (2023). “Phagocytosis in the retina promotes local insulin production in the eye.” Nature Metabolism 5(2): 207-218.

83. Imai, S., et al. (2023). “Estimation of Microvascular Dysfunction by Using 13N-Ammonia Positron Emission Tomography with Quantitative Myocardial Blood Flow Analysis in Chronic Coronary Syndrome.” Journal of Nippon Medical School 90(2): 228-236.

84. Ishii, H., et al. (2023). “Evaluation and improvement of CuI‐mediated 11C‐cyanation.” Journal of Labelled Compounds and Radiopharmaceuticals 66(3): 95-107.

85. Janovska, P., et al. (2023). “Impairment of adrenergically-regulated thermogenesis in brown fat of obesity-resistant mice is compensated by non-shivering thermogenesis in skeletal muscle.” Molecular Metabolism 69: 101683.

86. Jansen, T. J., et al. (2023). “Monitoring beta cell survival after intrahepatic islet transplantation using dynamic exendin PET imaging: a proof-of-concept study in individuals with type 1 diabetes.” Diabetes: db220884.

87. Janssen, B., et al. (2023). “Identification of a Putative α-synuclein Radioligand Using an in silico Similarity Search.” Molecular Imaging and Biology: 1-16.

88. Janssen, L., et al. (2023). “Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia.” American Journal of Physiology-Endocrinology and Metabolism 324(3): E209-E216.

89. Jiang, X., et al. (2023). “Altered limbic functional connectivity in individuals with subjective cognitive decline: Converging and diverging findings across Chinese and German cohorts.” Alzheimer’s & Dementia.

90. Jiao, J., et al. (2023). “NiftyPAD-Novel Python package for quantitative analysis of dynamic PET data.” Neuroinformatics 21(2): 457-468.

91. Jiao, R., et al. (2023). “A Theranostic Approach to Imaging and Treating Melanoma with 203Pb/212Pb-Labeled Antibody Targeting Melanin.” Cancers 15(15): 3856.

92. Johnson, B. N., et al. (2023). “PET imaging of kappa opioid receptors and receptor expression quantified in neuron-derived extracellular vesicles in socially housed female and male cynomolgus macaques.” Neuropsychopharmacology 48(2): 410-417.

93. Jonker, I., et al. (2023). “Antiviral treatment in schizophrenia: a randomized pilot PET study on the effects of valaciclovir on neuroinflammation.” Psychological Medicine: 1-9.

94. Kagitani-Shimono, K., et al. (2023). “Extension of microglial activation is associated with epilepsy and cognitive dysfunction in Tuberous sclerosis complex: A TSPO-PET study.” NeuroImage: Clinical 37: 103288.

95. Kapadia, A., et al. (2023). “Hypoperfusion Precedes Tau Deposition in the Entorhinal Cortex: A Retrospective Evaluation of ADNI-2 Data.” Journal of Clinical Neurology (Seoul, Korea) 19(2): 131.

96. Kasahara, S., et al. (2023). “Case report: Remission of chronic low back pain and oral dysesthesia comorbid with attention deficit/hyperactivity disorder by treatment with atomoxetine and pramipexole.” Frontiers in Pain Research 4: 1159134.

97. Kato, Y., et al. (2023). “Lower availability of mitochondrial complex I in anterior cingulate cortex in autism: a positron emission tomography study.” American Journal of Psychiatry 180(4): 277-284.

98. Katzdobler, S., et al. (2023). “Additive value of [18F] PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome.” European Journal of Nuclear Medicine and Molecular Imaging 50(2): 423-434.

99. Kersting, D., et al. (2023). “Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide Therapy.” Journal of Nuclear Medicine 64(2): 329-336.

100. Kesarwani, P., et al. (2023). “Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARγ signaling axis.” Nature Communications 14(1): 1459.

101. Kesić, M., et al. (2023). “Constitutive Serotonin Tone as a Modulator of Brown Adipose Tissue Thermogenesis: A Rat Study.” Life 13(7): 1436.

102. Kim, H., et al. (2023). “Magnetothermal-based non-invasive focused magnetic stimulation for functional recovery in chronic stroke treatment.” Scientific Reports 13(1): 4988.

103. Kim, J.-H., et al. (2023). “The Relationship between Character Traits and In Vivo Cerebral Serotonin Transporter Availability in Healthy Subjects: A High-Resolution PET Study with C-11 DASB.” Pharmaceuticals 16(5): 759.

104. Kim, M. S., et al. (2023). “Dual‐phase 18F‐FP‐CIT positron emission tomography and cardiac 123I‐MIBG scintigraphy of Parkinson’s disease patients with GBA mutations: evidence of the body‐first type?” European Journal of Neurology 30(2): 344-352.

105. Kim, S. B., et al. (2023). “Theranostic Surrogacy of [123I] NaI for Differentiated Thyroid Cancer Radionuclide Therapy.” Molecular Pharmaceutics.

106. Kim, S. J. W., et al. (2023). “A feasibility study for quantitative assessment of cerebrovascular malformations using flutriciclamide ([18F] GE-180) PET/MRI.” Frontiers in Medicine 10: 1091463.

107. Kitamura, S., et al. (2023). “Serotonergic neurotransmission in limbic regions may reflect therapeutic response of depressive patients: A PET study with 11C-WAY-100635 and 18F-MPPF.” International Journal of Neuropsychopharmacology: pyad026.

108. Ko, K.-Y., et al. (2023). “Myocardial Flow Assessment After Heart Transplantation Using Dynamic Cadmium-Zinc-Telluride Single-Photon Emission Computed Tomography With 201Tl and 99mTc Tracers and Validated by 13N-NH3 Positron Emission Tomography.” Circulation: Cardiovascular Imaging 16(6): e015034.

109. Kobayashi, R., et al. (2023). “In vivo [18F] THK-5351 imaging detected reactive astrogliosis in argyrophilic grain disease with comorbid pathology: A clinicopathological study.” Journal of Neuropathology & Experimental Neurology 82(5): 427-437.

110. Kroll, S. L., et al. (2023). “Plasma endocannabinoids in cocaine dependence and their interaction with cocaine craving and metabotropic glutamate receptor 5 density in the human brain.” bioRxiv: 2023.2004. 2018.537293.

111. Kubota, M., et al. (2023). “Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia.” Schizophrenia Bulletin 49(3): 688-696.

112. Kumagai, S., et al. (2023). “Early distribution of18 F‐labeled AAV9 vectors in the cerebrospinal fluid after intracerebroventricular or intracisternal magna infusion in non‐human primates.” The Journal of Gene Medicine 25(1): e3457.

113. Kunert, J.-P., et al. (2023). “Synthesis and preclinical evaluation of novel 99mTc-labeled PSMA ligands for radioguided surgery of prostate cancer.” EJNMMI research 13(1): 2.

114. Kunze, L. H., et al. (2023). “Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice.” International Journal of Molecular Sciences 24(12): 10106.

115. Laiglesia, L. M., et al. (2023). “Maresin 1 activates brown adipose tissue and promotes browning of white adipose tissue in mice.” Molecular Metabolism: 101749.

116. Lang, M., et al. (2023). “Static and dynamic 68Ga-FAPI PET/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas.” Journal of Nuclear Medicine 64(2): 244-251.

117. Lapo Pais, M., et al. (2023). “Textural properties of microglial activation in Alzheimer’s disease as measured by (R)-[11C] PK11195 PET.” Brain Communications 5(3): fcad148.

118. Lerchner, W., et al. (2023). “Current Research in Neurobiology.” Current Research in Neurobiology 4: 100091.

119. Lerchner, W., et al. (2023). “Efficient viral expression of a chemogenetic receptor in the old-world monkey amygdala.” Current Research in Neurobiology: 100091.

120. Levinstein, M. R., et al. (2023). “6-O-(2-[18F] Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([18F] FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo.” Molecular Imaging and Biology 25(2): 384-390.

121. Li, L., et al. (2023). “Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga] Ga-nanobody: from bench to bedside.” European Journal of Nuclear Medicine and Molecular Imaging: 1-15.

122. Li, L., et al. (2023). “Biodistribution and radiation dosimetry of multiple tracers on total-body positron emission tomography/computed tomography.” Quantitative Imaging in Medicine and Surgery 13(8): 5183.

123. Li, L.-F., et al. (2023). “Attenuation of Ventilation-Enhanced Epithelial–Mesenchymal Transition through the Phosphoinositide 3-Kinase-γ in a Murine Bleomycin-Induced Acute Lung Injury Model.” International Journal of Molecular Sciences 24(6): 5538.

124. Li, X., et al. (2023). “In situ-formed micro silk fibroin composite sutures for pain management and anti-infection.” Composites Part B: Engineering 260: 110729.

125. Li, Y., et al. (2023). “Fluorine-18-Labeled Diaryl-azines as Improved β-Amyloid Imaging Tracers: From Bench to First-in-Human Studies.” Journal of Medicinal Chemistry 66(7): 4603-4616.

126. Li, Z., et al. (2023). “Combination of pre-treatment dynamic [18F] FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma.” European Journal of Nuclear Medicine and Molecular Imaging 50(2): 535-545.

127. Liang, C., et al. (2023). “Abnormal [18F] NIFENE binding in transgenic 5xFAD mouse model of Alzheimer’s disease: In vivo PET/CT imaging studies of α4β2* nicotinic acetylcholinergic receptors and in vitro correlations with Aβ plaques.” Synapse 77(3): e22265.

128. Lin, H.-C., et al. (2023). “Visual reading for [18F] Florzolotau ([18F] APN-1607) tau PET imaging in clinical assessment of Alzheimer’s disease.” Frontiers in Neuroscience 17: 1148054.

129. Lin, Y.-S., et al. (2023). “Repeated Caffeine Intake Suppresses Cerebral Grey Matter Responses to Chronic Sleep Restriction in an A1 Adenosine Receptor-Dependent Manner.” bioRxiv: 2023.2007. 2023.550201.

130. Lindemann, M., et al. (2023). “Glioblastoma PET/MRI: kinetic investigation of [18F] rhPSMA-7.3,[18F] FET and [18F] fluciclovine in an orthotopic mouse model of cancer.” European Journal of Nuclear Medicine and Molecular Imaging 50(4): 1183-1194.

131. Lindheimer, F., et al. (2023). “Non-invasive in vivo imaging of porcine islet xenografts in a preclinical model with [68Ga] Ga-exendin-4.” Frontiers in Nuclear Medicine 3: 1157480.

132. Liu, G., et al. (2023). “Design, synthesis, and anti-inflammatory activity characterization of novel brain-permeable HDAC6 inhibitors.” European Journal of Medicinal Chemistry 254: 115327.

133. Liu, T., et al. (2023). “Synthesis and Preclinical Evaluation of 2-(4-[18F] Fluorophenyl) imidazo [1, 2-h][1, 7] naphthyridine ([18F] FPND-4): An Aza-Fused Tricyclic Derivative as Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging.” Journal of Medicinal Chemistry.

134. Longo, M., et al. (2023). “Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria.” International Journal of Molecular Sciences 24(15): 11938.

135. Lu, J., et al. (2023). “YY1 (Yin‐Yang 1), a transcription factor regulating systemic inflammation, is involved in cognitive impairment of depression.” Psychiatry and Clinical Neurosciences 77(3): 149-159.

136. Lu, J., et al. (2023). “Blood tau‐PT217 contributes to the anesthesia/surgery‐induced delirium‐like behavior in aged mice.” Alzheimer’s & Dementia.

137. Lu, X., et al. (2023). “68Ga-labeled WVP peptide as a novel PET probe for molecular biological diagnosis of unstable thoracic aortic aneurysm and early dissection: an animal study.” Frontiers in Cardiovascular Medicine 10: 1048927.

138. Ma, Y., et al. (2023). “Effects of Dl-3-n-butylphthalide on cognitive functions and blood–brain barrier in chronic cerebral hypoperfusion rats.” Naunyn-Schmiedeberg’s archives of pharmacology: 1-14.

139. Mannheim, J. G., et al. (2023). “Characterization of the partial volume effect along the axial field-of-view of the Biograph Vision Quadra total-body PET/CT system for multiple isotopes.” EJNMMI physics 10(1): 1-16.

140. Maric, I., et al. (2023). “Efficacy and Safety of 124I-MIBG Dosimetry-Guided High-Activity 131I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma.” Journal of Nuclear Medicine 64(6): 885-891.

141. Martín-Saladich, Q., et al. (2023). “Insights into Insulin Resistance and Calcification in the Myocardium in Type 2 Diabetes: A Coronary Artery Analysis.” International Journal of Molecular Sciences 24(4): 3250.

142. Matsumoto, Y., et al. (2023). “Rapidly progressive cerebral atrophy following a posterior cranial fossa stroke: Assessment with semiautomatic CT volumetry.” Acta Neurochirurgica: 1-10.

143. Matsunaga, K., et al. (2023). “Effect of scan-time shortening on the 11C-PHNO binding potential to dopamine D3 receptor in humans and test–retest reliability.” Annals of Nuclear Medicine 37(4): 227-237.

144. Matsuoka, K., et al. (2023). “Association of Glutamate and N-Acetylaspartate Levels with Abnormal Protein Deposition in Alzheimer’s Disease: Insights from Magnetic Resonance Spectroscopic Imaging.” medRxiv: 2023.2004. 2023.23288989.

145. Matthews, D. C., et al. (2022). “Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier.” Alzheimer’s & Dementia: Translational Research & Clinical Interventions 8(1): e12325.

146. McClain, S. P., et al. (2023). “In vivo photopharmacology with light-activated opioid drugs.” bioRxiv: 2023.2002. 2002.526901.

147. Michiels, L., et al. (2023). “Longitudinal Synaptic Density PET with 11C‐UCB‐J 6 Months After Ischemic Stroke.” Annals of Neurology 93(5): 911-921.

148. Michiels, L., et al. (2023). “In Vivo Detection of Neurofibrillary Tangles by 18F-MK-6240 PET/MR in Patients With Ischemic Stroke.” Neurology 100(1): e62-e71.

149. Mills, K. A., et al. (2023). “Microglial CSF1R radioligand [11C] CPPC as a marker of disease severity in early Parkinson′ s disease: a pilot study.” medRxiv: 2023.2005. 2028.23290647.

150. Mingels, C., et al. (2023). “Impact of the new ultra-high sensitivity mode in a long axial field-of-view PET/CT.” Annals of Nuclear Medicine 37(5): 310-315.

151. Miranda, A., et al. (2023). “Isoflurane and ketamine-xylazine modify pharmacokinetics of [18F] SynVesT-1 in the mouse brain.” Journal of Cerebral Blood Flow & Metabolism: 0271678X231173185.

152. Miwa, K., et al. (2023). “Impact of γ factor in the penalty function of Bayesian penalized likelihood reconstruction (Q. Clear) to achieve high-resolution PET images.” EJNMMI physics 10(1): 4.

153. Miyakawa, N., et al. (2023). “Chemogenetic attenuation of cortical seizures in nonhuman primates.” Nature Communications 14(1): 971.

154. Miyamoto, M., et al. (2023). “Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects.” Annals of Nuclear Medicine 37(5): 300-309.

155. Moallemian, S., et al. (2023). “Multimodal imaging of microstructural cerebral changes and loss of synaptic density in Alzheimer’s disease.” medRxiv: 2023.2004. 2014.23288516.

156. Mohri, K., et al. (2023). “Lasso peptide microcin J25 variant containing RGD motif as a PET probe for integrin av ß 3 in tumor imaging.” European Journal of Pharmaceutical Sciences 180: 106339.

157. Morley, V., et al. (2023). “In vivo18F-DOPA PET imaging identifies a dopaminergic deficit in a rat model with a G51D α-synuclein mutation.” Frontiers in Neuroscience 17: 1095761.

158. Müller, L., et al. (2023). “Excitability and glymphatic function in an animal model of Alzheimer’s disease.” Alzheimer’s & Dementia 19: e059591.

159. Müller, L., et al. (2023). “[18F] GE-180-PET and Post Mortem Marker Characteristics of Long-Term High-Fat-Diet-Induced Chronic Neuroinflammation in Mice.” Biomolecules 13(5): 769.

160. Munk, D. E., et al. (2023). “Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders.” JoVE (Journal of Visualized Experiments)(194): e65109.

161. Murce, E., et al. (2023). “Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics.” Pharmaceuticals 16(6): 882.

162. Murgaš, M., et al. (2023). “Effects of bilateral sequential theta-burst stimulation on 5-HT1A receptors in the dorsolateral prefrontal cortex in treatment-resistant depression: a proof-of-concept trial.” Translational Psychiatry 13(1): 33.

163. Nagai, Y. and T. Minamimoto (2023). Methods to Verify Expression and Function of DREADDs Using PET. Vectorology for Optogenetics and Chemogenetics, Springer: 263-273.

164. Nguyen, D., et al. (2023). “Development of a rat model of lymphedema and the implantation of a collagen-based medical device for therapeutic intervention.” Frontiers in Cardiovascular Medicine 10.

165. Nguyen, T. D. T., et al. (2023). “Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time.” Cancer Research 83(6): 939-955.

166. Ni, R., et al. (2023). “Imaging increased metabolism in the spinal cord in mice after middle cerebral artery occlusion.” Photoacoustics 32: 100532.

167. Niwa, T., et al. (2023). “Synthesis of 11C-Radiolabeled Eribulin as a Companion Diagnostics PET Tracer for Brain Glioblastoma.” Bulletin of the Chemical Society of Japan 96(3): 283-290.

168. Oh, S. J., et al. (2023). “Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression.” Molecular Imaging and Biology: 1-9.

169. Oh, S. J., et al. (2023). “Effect of developmental stress on the in vivo neuronal circuits related to excitation–inhibition balance and mood in adulthood.” Frontiers in Psychiatry 14: 1086370.

170. Ohnishi, A., et al. (2023). “Dosimetry and efficacy of a tau PET tracer [18F] MK-6240 in Japanese healthy elderly and patients with Alzheimer’s disease.” Annals of Nuclear Medicine 37(2): 108-120.

171. O’Neill, E., et al. (2023). “Imaging DNA damage response by γH2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome.” Theranostics 13(4): 1302.

172. Ote, K., et al. (2023). “List-mode PET image reconstruction using deep image prior.” IEEE Transactions on Medical Imaging.

173. Ou, G., et al. (2023). “Methylene blue targets PHD3 expression in murine microglia to mitigate lipopolysaccharide-induced neuroinflammation and neurocognitive impairments.” International Immunopharmacology 120: 110349.

174. Oya, M., et al. (2023). “Increased glutamate and glutamine levels and their relationship to astrocytes and dopaminergic transmissions in the brains of adults with autism.” Scientific Reports 13(1): 11655.

175. Pantel, A. R., et al. (2023). “[18F] FluorThanatrace ([18F] FTT) PET imaging of PARP-inhibitor drug-target engagement as a biomarker of response in ovarian cancer, a pilot study.” Clinical Cancer Research 29(8): 1515-1527.

176. Park, D. G., et al. (2023). “Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder.” Journal of Neurology: 1-10.

177. Park, H. S., et al. (2023). “A robust multi-domain network for short-scanning amyloid PET reconstruction.” arXiv preprint arXiv:2305.09986.

178. Park, J., et al. (2023). “Combined Effects of Focused Ultrasound and Photodynamic Treatment for Malignant Brain Tumors Using C6 Glioma Rat Model.” Yonsei Medical Journal 64(4): 233.

179. Passannante, R., et al. (2023). “Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Candidate with Potential Application in Neuromuscular Disorders.” Biomedicines 11(2): 253.

180. Pauwels, E., et al. (2023). “[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients.” European Journal of Nuclear Medicine and Molecular Imaging 50(4): 1134-1145.

181. Peñalva, R., et al. (2023). “Encapsulation of Lactobacillus plantarum in casein-chitosan microparticles facilitates the arrival to the colon and develops an immunomodulatory effect.” Food Hydrocolloids 136: 108213.

182. Peyronneau, M., et al. (2023). “[18F] DPA-714: Effect of co-medications, age, sex, BMI and TSPO polymorphism on the human plasma input function.” European Journal of Nuclear Medicine and Molecular Imaging: 1-14.

183. Pistone, D., et al. (2023). “18F-PSMA-1007 salivary gland dosimetry: comparison between different methods for dose calculation and assessment of inter-and intra-patient variability.” Physics in Medicine & Biology 68(8): 085015.

184. Poply, K., et al. (2023). “ID: 213463 Dynamic Brain Imaging Response to SCS Differential Frequencies:(DIFY SCS-PET), A Pilot Double-Blind Clinical Trial.” Neuromodulation 26(4): S133.

185. Poxleitner, M., et al. (2023). “Western diet increases brain metabolism and adaptive immune responses in a mouse model of amyloidosis.” bioRxiv: 2023.2002. 2015.528645.

186. Puri, T., et al. (2023). “Input function and modeling for determining bone metabolic flux using [18F] sodium fluoride PET imaging: A step‐by‐step guide.” Medical Physics 50(4): 2071-2088.

187. Puuvuori, E., et al. (2023). “PET imaging of neutrophil elastase with 11C-GW457427 in Acute Respiratory Distress Syndrome in pigs.” Journal of Nuclear Medicine 64(3): 423-429.

188. Qiao, N., et al. (2023). “Kinsenoside alleviates oxidative stress-induced blood-brain barrier dysfunction via promoting Nrf2/HO-1 pathway in ischemic stroke.” European Journal of Pharmacology 949: 175717.

189. Qiu, L., et al. (2023). “Discovery of a Promising Fluorine-18 Positron Emission Tomography Radiotracer for Imaging Sphingosine-1-Phosphate Receptor 1 in the Brain.” Journal of Medicinal Chemistry 66(7): 4671-4688.

190. Rainio, O., et al. (2023). “Carimas: an extensive medical imaging data processing tool for research.” Journal of Digital Imaging: 1-9.

191. Rauber, S., et al. (2023). “Molecular Imaging with Fibroblast Activation Protein Tracers Depicts Inflammatory Joint Damage and Its Transition to Resolution of Inflammation.” bioRxiv: 2023.2001. 2017.524425.

192. Read, A. D., et al. (2023). “Electron Leak From the Mitochondrial Electron Transport Chain Complex I at Site IQ Is Crucial for Oxygen Sensing in Rabbit and Human Ductus Arteriosus.” Journal of the American Heart Association: e029131.

193. Reed, M. B., et al. (2023). “Comparison of cardiac image-derived input functions for quantitative whole body [18F] FDG imaging with arterial blood sampling.” Frontiers in Physiology 14: 1074052.

194. Resch, S., et al. (2023). “Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition.” EJNMMI physics 10(1): 11.

195. Rimmerman, E. T., et al. (2023). “Vessel-by-Vessel Computed Tomography Calcium Scoring of the Foot in Peripheral Artery Disease: Association with Patient-Level Factors.” Advances in Wound Care.

196. Ríos, C., et al. (2023). “Characterization of the anticonvulsant effect of dapsone on metabolic activity assessed by [18F] FDG-PET after kainic acid-induced status epilepticus in rats.” Brain Research 1803: 148227.

197. Robert, S. M., et al. (2023). “The choroid plexus links innate immunity to CSF dysregulation in hydrocephalus.” Cell 186(4): 764-785. e721.

198. Robertson, N., et al. (2023). “Omniparticle Contrast Agent for Multimodal Imaging: Synthesis and Characterization in an Animal Model.” Molecular Imaging and Biology 25(2): 401-412.

199. Rua, M., et al. (2023). “Infection-specific PET imaging with 18F-fluorodeoxysorbitol and 2-[18F] F-ρ-aminobenzoic acid: An extended diagnostic tool for bacterial and fungal diseases.” Frontiers in Microbiology 14: 1094929.

200. Rubin, L. H., et al. (2023). “Pilot imaging of the colony stimulating factor 1 receptor in the brains of virally-suppressed individuals with HIV.” AIDS: 10.1097.

201. Sachpekidis, C., et al. (2023). “Application of the long axial field-of-view PET/CT with low-dose [18F] FDG in melanoma.” European Journal of Nuclear Medicine and Molecular Imaging 50(4): 1158-1167.

202. Sari, H., et al. (2023). “Feasibility of using abbreviated scan protocols with population-based input functions for accurate kinetic modeling of [18F]-FDG datasets from a long axial FOV PET scanner.” European Journal of Nuclear Medicine and Molecular Imaging 50(2): 257-265.

203. Sarrhini, O., et al. (2023). “Enhanced Extraction of Blood and Tissue Time-Activity Curves in Cardiac Mouse FDG PET Imaging by Means of Constrained Nonnegative Matrix Factorization.” International Journal of Biomedical Imaging 2023.

204. Sasaki, K., et al. (2023). “Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys.” Journal of Controlled Release 359: 384-399.

205. Schadt, F., et al. (2023). “Analysis of cerebral glucose metabolism following experimental subarachnoid hemorrhage over 7 days.” Scientific Reports 13(1): 427.

206. Schindler, L., et al. (2022). “Neurotensin analogs by fluoroglycosylation at N ω-carbamoylated arginines for PET imaging of NTS1-positive tumors.” Scientific Reports 12(1): 15028.

207. Schollhammer, R., et al. (2023). “Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study.” Journal of Nuclear Medicine 64(3): 379-385.

208. Seibyl, J. P., et al. (2023). “A visual interpretation algorithm for assessing brain tauopathy with 18F-MK-6240 PET.” Journal of Nuclear Medicine 64(3): 444-451.

209. Seifert, P., et al. (2023). “Optimization of Thyroid Volume Determination by Stitched 3D-Ultrasound Data Sets in Patients with Structural Thyroid Disease.” Biomedicines 11(2): 381.

210. Seo, Y., et al. (2023). “Endogenous Neural Stem Cell Activation after Low-Intensity Focused Ultrasound-Induced Blood–Brain Barrier Modulation.” International Journal of Molecular Sciences 24(6): 5712.

211. Settelmeier, S., et al. (2023). “Demonstration of the Early Cardiac Bioavailability of a Non-Specific Cell-Targeted Peptide Using Radionuclide-Based Imaging In Vivo.” Pharmaceuticals 16(6): 824.

212. Shao, D., et al. (2023). “Brain glucose metabolism and dopamine transporter changes in rats with morphine‐induced conditioned place preference.” Addiction Biology 28(5): e13277.

213. Shao, X., et al. (2023). “Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy—a study based on 18 F-FDG microPET myocardial metabolic imaging.” Diabetology & Metabolic Syndrome 15(1): 64.

214. Sharma, G., et al. (2023). “Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma.” Cancers 15(12): 3131.

215. Shimohama, S., et al. (2023). “Impact of amyloid and tau PET on changes in diagnosis and patient management.” Neurology 100(3): e264-e274.

216. Shin, H., et al. (2023). “Vision Transformer Approach for Classification of Alzheimer’s Disease Using 18F-Florbetaben Brain Images.” Applied Sciences 13(6): 3453.

217. Simo, C., et al. (2023). “Positron Emission Tomography Studies of the Biodistribution, Translocation, and Fate of Poly Allyl Amine‐Based Carriers for Sirna Delivery by Systemic and Intratumoral Administration.” Small: 2304326.

218. Simón, J. A., et al. (2023). “Radiolabeled risperidone microSPECT/CT imaging for intranasal implant studies development.” Pharmaceutics 15(3): 843.

219. Simon, K. S., et al. (2023). “Innovative Pre-Clinical Data Using Peptides to Intervene in the Evolution of Pulmonary Fibrosis.” International Journal of Molecular Sciences 24(13): 11049.

220. Simpson, S. R., et al. (2023). “Imaging Diverse Pathogenic Bacteria In Vivo with 18F-Fluoromannitol PET.” Journal of Nuclear Medicine 64(5): 809-815.

221. Slowing, K., et al. (2023). “PET imaging and neurohistochemistry reveal that curcumin attenuates brain hypometabolism and hippocampal damage induced by status epilepticus in rats.” Planta Medica 89(04): 364-376.

222. Smucny, J., et al. (2023). “Increased Striatal Presynaptic Dopamine in a Nonhuman Primate Model of Maternal Immune Activation: A Longitudinal Neurodevelopmental Positron Emission Tomography Study With Implications for Schizophrenia.” Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 8(5): 505-513.

223. Solingapuram Sai, K. K., et al. (2023). “Effect of Electronic Cigarette Liquid pH on Retention of 11C-Nicotine in a Respiratory Tract Model.” Nicotine and Tobacco Research 25(7): 1406-1410.

224. Son, S. H., et al. (2023). “Brain FDG PET for visualizing the relation between impaired lung function and cognitive decline in lung cancer: a preliminary study.” Nuclear Medicine Communications 44(6): 488-494.

225. Song, A. K., et al. (2023). “Parasagittal dural space hypertrophy and amyloid-β deposition in Alzheimer’s disease.” Brain Communications 5(3): fcad128.

226. Soyer, A., et al. (2023). “Validation of a pharmacological imaging challenge using 11C-buprenorphine and 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography to study the effects of buprenorphine to the rat brain.” Frontiers in Neuroscience 17: 1181786.

227. Spies, M., et al. (2023). “Impact of genetic variants within serotonin turnover enzymes on human cerebral monoamine oxidase A in vivo.” Translational Psychiatry 13(1): 208.

228. Staanum, P. F. (2023). “Tumor dosimetry using 177Lu: influence of background activity, measurement method and reconstruction algorithm.” EJNMMI physics 10(1): 1-22.

229. Straat, M. E., et al. (2023). “Stimulation of the beta-2-adrenergic receptor with salbutamol activates human brown adipose tissue.” Cell Reports Medicine 4(2).

230. Suchacki, K. J., et al. (2023). “The serotonin transporter sustains human brown adipose tissue thermogenesis.” Nature Metabolism: 1-18.

231. Tada, T., et al. (2023). “Comparative examination of the pons and corpus callosum as reference regions for quantitative evaluation in positron emission tomography imaging for Alzheimer’s disease using 11C-Pittsburgh Compound-B.” Annals of Nuclear Medicine: 1-9.

232. Takakuwa, N., et al. (2023). “Protocol for making an animal model of “blindsight” in macaque monkeys.” STAR protocols 4(1): 101960.

233. Takita, H., et al. (2023). “Correlation between Phase-difference-enhanced MR Imaging and Amyloid Positron Emission Tomography: A Study on Alzheimer’s Disease Patients and Normal Controls.” Magnetic Resonance in Medical Sciences 22(1): 67-78.

234. Tanada, T., et al. (2023). “Quantification of myocardial blood flow and myocardial flow reserve by 13N-NH3 PET/CT is not significantly affected by pixel size.” The International Journal of Cardiovascular Imaging 39(1): 195-199.

235. Tang, J. M., et al. (2023). “A Protocol for Simultaneous In Vivo Imaging of Cardiac and Neuroinflammation in Dystrophin-Deficient MDX Mice Using [18F] FEPPA PET.” International Journal of Molecular Sciences 24(8): 7522.

236. Thanapornsangsuth, P., et al. (2023). “Prospective evaluation of plasma phosphorylated tau in a real‐life memory clinic in Thailand.” Alzheimer’s & Dementia.

237. Tichelman, N. L., et al. (2023). “A genetic variation in the adenosine A2A receptor gene contributes to variability in oscillatory alpha power in wake and sleep EEG and A1 adenosine receptor availability in the human brain.” bioRxiv: 2023.2003. 2001.530170.

238. Trang, N. N., et al. (2023). “Ketogenic diet modulates cardiac metabolic dysregulation in streptozocin-induced diabetic rats.” The Journal of Nutritional Biochemistry 111: 109161.

239. Tsai, Y. T., et al. (2023). “Social cognitive deficit is associated with visuomotor coordination impairment and dopamine transporter availability in euthymic bipolar disorder.” Journal of Psychiatric Research.

240. Tsuchihashi, S., et al. (2023). “Development of Novel 111In/225Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics.” Journal of Medicinal Chemistry.

241. Ueberham, L., et al. (2023). “Development of the High-Affinity Carborane-Based Cannabinoid Receptor Type 2 PET Ligand [18F] LUZ5-d 8.” Journal of Medicinal Chemistry 66(7): 5242-5260.

242. Unda, S. R., et al. (2023). “Bidirectional Regulation of Motor Circuits Using Magnetogenetic Gene Therapy.” bioRxiv: 2023.2007. 2013.548699.

243. Urano, E., et al. (2023). “An engineered ACE2 decoy broadly neutralizes omicron subvariants and shows therapeutic effect in SARS-CoV-2-infected cynomolgus macaques.” bioRxiv: 2022.2012. 2029.522275.

244. van Der Hoek, S., et al. (2023). “Feasibility Study to Assess Canagliflozin Distribution and Sodium‐Glucose Co‐Transporter 2 Occupancy Using [18F] Canagliflozin in Patients with Type 2 Diabetes.” Clinical Pharmacology & Therapeutics 113(6): 1295-1303.

245. van Dijk, B., et al. (2023). “Evaluating the Targeting of a Staphylococcus-aureus-Infected Implant with a Radiolabeled Antibody In Vivo.” International Journal of Molecular Sciences 24(5): 4374.

246. Vivian, G. K., et al. (2023). “The interaction between aging and protein malnutrition modulates peritoneal macrophage function: An experimental study in male mice.” Experimental Gerontology 171: 112025.

247. Voci, S., et al. (2023). “Gliadin nanoparticles for oral administration of bioactives: Ex vivo and in vivo investigations.” International Journal of Biological Macromolecules: 126111.

248. Vogler, L., et al. (2023). “Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [18F] UCB-H PET imaging.” NeuroImage: Clinical: 103484.

249. Völter, F., et al. (2023). “Assessment of perfusion deficit with early phases of [18F] PI-2620 tau-PET versus [18F] flutemetamol-amyloid-PET recordings.” European Journal of Nuclear Medicine and Molecular Imaging 50(5): 1384-1394.

250. Wagatsuma, K., et al. (2023). “Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study.” Annals of Nuclear Medicine: 1-10.

251. Wang, H., et al. (2023). “A new 68Ga-labeled ornithine derivative for PET imaging of ornithine metabolism in tumors.” Amino Acids: 1-12.

252. Wang, L., et al. (2023). “Identifying sex-specific risk architectures for predicting amyloid deposition using neural networks.” NeuroImage 275: 120147.

253. Wang, X., et al. (2023). “A novel decellularized matrix of Wnt signaling-activated osteocytes accelerates the repair of critical-sized parietal bone defects with osteoclastogenesis, angiogenesis, and neurogenesis.” Bioactive Materials 21: 110-128.

254. Wang, Z., et al. (2023). “Deconvolution of Plasma Pharmacokinetics from Dynamic Heart Imaging Data Obtained by Single Positron Emission Computed Tomography/Computed Tomography Imaging.” Journal of Pharmacology and Experimental Therapeutics 386(1): 102-110.

255. Warashina, S., et al. (2023). “Two-Chain Mature Hepatocyte Growth Factor-Specific Positron Emission Tomography Imaging in Tumors Using 64Cu-Labeled HiP-8, a Nonstandard Macrocyclic Peptide Probe.” Molecular Pharmaceutics 20(4): 2029-2038.

256. Werner, A., et al. (2023). “Liver PET Reloaded: Automated Synthesis of [68Ga] Ga-BP-IDA for Positron Imaging of the Hepatobiliary Function and First Clinical Experience.” Diagnostics 13(6): 1144.

257. Wetherill, R. R., et al. (2023). “Molecular Imaging of Pulmonary Inflammation in Users of Electronic and Combustible Cigarettes: A Pilot Study.” Journal of Nuclear Medicine 64(5): 797-802.

258. White, J. M., et al. (2023). “Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer.” Theranostics 13(7): 2057.

259. Wichmann, C. W., et al. (2023). “Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.” Nuclear Medicine and Biology: 108366.

260. Willuweit, A., et al. (2023). “Evaluation of the 18F-labeled analog of the therapeutic all-D-enantiomeric peptide RD2 for amyloid β imaging.” European Journal of Pharmaceutical Sciences 184: 106421.

261. Wollring, M. M., et al. (2023). “Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.” Neuro-oncology 25(5): 984-994.

262. Xin, M., et al. (2023). “Pilot study on 11C-CFT dynamic imaging using total-body PET/CT: biodistribution and radiation dosimetry in Parkinson’s disease.” Frontiers in Neurology 14: 1153779.

263. Xiong, M., et al. (2023). “Synaptic density in aging mice measured by [18F] SynVesT-1 PET.” NeuroImage: 120230.

264. Yamasaki, T., et al. (2023). “Small-animal PET study for noninvasive quantification of transmembrane AMPA receptor regulatory protein γ-8 (TARP γ-8) in the brain.” Journal of Cerebral Blood Flow & Metabolism 43(6): 893-904.

265. Yan, X., et al. (2023). “In vivo evaluation of a novel 18F-labeled PET radioligand for translocator protein 18 kDa (TSPO) in monkey brain.” European Journal of Nuclear Medicine and Molecular Imaging: 1-9.

266. Yang, X., et al. (2023). “Brain glucose metabolism on [18F]-FDG PET/CT: a dynamic biomarker predicting depression and anxiety in cancer patients.” Frontiers in Oncology 13: 1098943.

267. Yang, Z., et al. (2023). “Associations of striatal dopamine transporter binding with motor and non‐motor symptoms in early Parkinson’s disease.” Clinical and Translational Science.

268. Yasuno, F., et al. (2023). “Involvement of inflammation in the medial temporal region in the development of agitation in Alzheimer’s disease: an in vivo positron emission tomography study.” Psychogeriatrics 23(1): 126-135.

269. Ye, P., et al. (2023). “Activated Microglia in the Early Stage of a Rat Model of Parkinson’s Disease: Revealed by PET-MRI Imaging by [18F] DPA-714 Targeting TSPO.” ACS Chemical Neuroscience 14(11): 2183-2192.

270. Yin, H., et al. (2023). “Dynamic Total-Body PET/CT Imaging Reveals Kinetic Distribution of 68 Ga-DOTATATE in Normal Organs.” Contrast Media & Molecular Imaging 2023.

271. Yoganathan, T., et al. (2023). “Acute stress induces long-term metabolic, functional, and structural remodeling of the heart.” Nature Communications 14(1): 3835.

272. Yoo, C.-H., et al. (2023). “Evaluation of [18F] PF-06455943 as a Potential LRRK2 PET Imaging Agent in the Brain of Nonhuman Primates.” ACS Chemical Neuroscience 14(3): 370-377.

273. Yoshizawa, T., et al. (2023). “Working memory-based and-free reward prediction in a dual dopamine system in the basal ganglia.” bioRxiv: 2023.2003. 2006.531239.

274. Yu, A.-L., et al. (2023). “Tafamidis Treatment Decreases 99mTc-Pyrophosphate Uptake in Patients With Hereditary Ala97Ser Transthyretin Amyloid Cardiomyopathy.” Cardiovascular Imaging 16(6): 866-867.

275. Yu, X., et al. (2023). “Improved accuracy of the biodistribution and internal radiation dosimetry of 13N‐ammonia using a total‐body PET/CT scanner.” Medical Physics.

276. Yuan, G., et al. (2023). “PET imaging studies to investigate functional expression of mGluR2 using [11C] mG2P001.” Journal of Cerebral Blood Flow & Metabolism 43(2): 296-308.

277. Yuki, Y., et al. (2023). “Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates.” Vaccine 41(34): 4941-4949.

278. Zablocki-Thomas, P. B., et al. (2023). “Neural correlates and effect of jealousy on cognitive flexibility in the female titi monkey (Plecturocebus cupreus).” Hormones and Behavior 152: 105352.

279. Zatcepin, A., et al. (2023). “Machine learning-based approach reveals essential features for simplified TSPO PET quantification in ischemic stroke patients.” Zeitschrift für Medizinische Physik.

280. Zerweck, L., et al. (2023). “Evaluation of the cerebrovascular reactivity in patients with Moyamoya Angiopathy by use of breath-hold fMRI: investigation of voxel-wise hemodynamic delay correction in comparison to [15O] water PET.” Neuroradiology 65(3): 539-550.

281. Zhang, Y., et al. (2023). “Development and characterization of nanobody-derived CD47 theranostic pairs in solid tumors.” Research 6: 0077.

282. Zheng, W., et al. (2023). “Synthesis and In Vitro and In Vivo Evaluation of 18F-Labeled Positron Emission Tomography Tracers for Imaging Aβ Plaques.” ACS Chemical Neuroscience 14(5): 988-1003.

283. Zhou, D., et al. (2023). “Long-term dietary folic acid supplementation attenuated aging-induced hippocampus atrophy and promoted glucose uptake in 25-month-old rats with cognitive decline.” The Journal of Nutritional Biochemistry 117: 109328.

284. Zhou, W., et al. (2023). “Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers.” Molecular Cancer Therapeutics: MCT-22-0743.

285. Zhu, W., et al. (2023). “Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.” European Journal of Nuclear Medicine and Molecular Imaging: 1-10.

286. Zounek, A. J., et al. (2023). “Feasibility of radiomic feature harmonization for pooling of [18F] FET or [18F] GE-180 PET images of gliomas.” Zeitschrift für Medizinische Physik 33(1): 91-102.